icon-    folder.gif   Conference Reports for NATAP  
  17th CROI
Conference on Retroviruses
and Opportunistic Infections
San Francisco CA
February 16-19, 2010
Back grey_arrow_rt.gif
Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-Experienced Patients Enrolled Into the MOTIVATE Studies and Who Received Maraviroc + Optimized Background Therapy
  Reported by Jules Levin
CROI 2010 SF, Feb 16-19
Marilyn Lewis1, Paul Simpson1, Christophe Delogne1, John Sullivan1, Hernan Valdez3, Richard Harrigan2 and Mike Westby1 1Pfizer Global R&D, Sandwich, Kent, UK; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3Pfizer Inc. New York, NY